Potential Clinical Applications of PET/MR

Since the introduction of simultaneous positron emission tomography magnetic resonance imaging (PET/MR) in 2010, technological advances led to improved image quality, improved attenuation correction, and reduced scan time, leading to an increasing number of clinical applications for this new technology. Lower radiation exposure and higher soft-tissue contrast are the main advantages of PET/MR over PET/CT. However, its real added value in clinical applications is still under investigation. This short review is focusing on three PET/MR applications that had an increasing clinical acceptance in our institution and where we believe that PET/MR will play an important role in the future: prostate cancer, head and neck cancer, and cardiac imaging.

[1]  G. Hör,et al.  Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer , 1998, European Journal of Nuclear Medicine.

[2]  Olivier Rouvière,et al.  MRI Appearance of Prostate following Transrectal HIFU Ablation of Localized Cancer , 2001, European Urology.

[3]  S. Stoeckli,et al.  Head and neck squamous cell carcinoma (HNSCC) – detection of synchronous primaries with 18F-FDG-PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  J. Roodenburg,et al.  18F-FDG PET as a Routine Posttreatment Surveillance Tool in Oral and Oropharyngeal Squamous Cell Carcinoma: A ProspectiveStudy , 2009, Journal of Nuclear Medicine.

[5]  Françoise Kraeber-Bodéré,et al.  Does 18F-FDG PET/CT Improve the Detection of Posttreatment Recurrence of Head and Neck Squamous Cell Carcinoma in Patients Negative for Disease on Clinical Follow-up? , 2008, Journal of Nuclear Medicine.

[6]  Bernd J. Pichler,et al.  Feasibility of simultaneous PET/MR imaging in the head and upper neck area , 2011, European Radiology.

[7]  S. Pavlović,et al.  The Utility of 18F-FDG PET/CT for Diagnosis and Adjustment of Therapy in Patients with Active Chronic Sarcoidosis , 2012, The Journal of Nuclear Medicine.

[8]  M. Soyka,et al.  Improved treatment outcomes with 18F‐FDG PET/CT for patients with advanced head and neck squamous cell carcinoma , 2012, Head & neck.

[9]  M. Lubberink,et al.  In Vivo Visualization of Amyloid Deposits in the Heart with 11C-PIB and PET , 2013, The Journal of Nuclear Medicine.

[10]  Jon Hainer,et al.  Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. , 2012, Journal of the American College of Cardiology.

[11]  T. Holland-Letz,et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Amit R. Patel,et al.  HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. , 2014, Heart rhythm.

[13]  W. Weber.  PET/MR Imaging: A Critical Appraisal , 2014, The Journal of Nuclear Medicine.

[14]  M. Fishbein,et al.  Cardiac Involvement in Sarcoidosis: Evolving Concepts in Diagnosis and Treatment , 2014, Seminars in Respiratory and Critical Care Medicine.

[15]  Stephan G. Nekolla,et al.  68Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer , 2015, Abdominal Imaging.

[16]  N. Tamaki,et al.  Current status of nuclear cardiology in Japan: Ongoing efforts to improve clinical standards and to establish evidence , 2015, Journal of Nuclear Cardiology.

[17]  Gerald Antoch,et al.  Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  G. Cheon,et al.  Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous 18F-fluorocholine PET/MRI for primary prostate cancer characterization , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  A. Pisani,et al.  First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  P. Heusch,et al.  Integrated 18F-FDG PET/MR Imaging in the Assessment of Cardiac Masses: A Pilot Study , 2015, The Journal of Nuclear Medicine.

[21]  S. Sheikhbahaei,et al.  FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. , 2016, AJR. American journal of roentgenology.

[22]  H. Verberne,et al.  Additional Heparin Preadministration Improves Cardiac Glucose Metabolism Suppression over Low-Carbohydrate Diet Alone in 18F-FDG PET Imaging , 2016, The Journal of Nuclear Medicine.

[23]  P. Korsten,et al.  Management of extrapulmonary sarcoidosis: challenges and solutions , 2016, Therapeutics and clinical risk management.

[24]  H. Zaidi,et al.  Local recurrence of squamous cell carcinoma of the head and neck after radio(chemo)therapy: Diagnostic performance of FDG-PET/MRI with diffusion-weighted sequences , 2017, European Radiology.

[25]  R. Herfkens,et al.  Initial Experience With Simultaneous 18F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis , 2017, Clinical nuclear medicine.

[26]  Tetsuro Sekine,et al.  Local resectability assessment of head and neck cancer: Positron emission tomography/MRI versus positron emission tomography/CT , 2017, Head & neck.

[27]  H. Merisaari,et al.  Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial) , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  S. Kollias,et al.  PET+MR versus PET/CT in the initial staging of head and neck cancer, using a trimodality PET/CT+MR system. , 2017, Clinical imaging.

[29]  Jeong Hyun Lee,et al.  18F-FDG PET/CT surveillance for the detection of recurrence in patients with head and neck cancer. , 2017, European journal of cancer.

[30]  Andrew P. Leynes,et al.  Hybrid ZTE/Dixon MR‐based attenuation correction for quantitative uptake estimation of pelvic lesions in PET/MRI , 2017, Medical physics.

[31]  F. Bidault,et al.  Diagnostic and prognostic value of 18F-FDG PET, CT, and MRI in perineural spread of head and neck malignancies , 2018, European Radiology.

[32]  A. Stenzinger,et al.  Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  Kirsten L. Greene,et al.  Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer , 2017, EJNMMI Research.

[34]  I. Burger,et al.  Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  Thierry Blu,et al.  MR‐based respiratory and cardiac motion correction for PET imaging , 2017, Medical Image Anal..

[36]  Nicolas A Karakatsanis,et al.  Correction of respiratory and cardiac motion in cardiac PET/MR using MR-based motion modeling , 2018, Physics in medicine and biology.

[37]  E. V. van Beek,et al.  Multimodality Quantitative Assessments of Myocardial Perfusion Using Dynamic Contrast Enhanced Magnetic Resonance and 15O-Labeled Water Positron Emission Tomography Imaging , 2018, IEEE Transactions on Radiation and Plasma Medical Sciences.

[38]  Kirsten L. Greene,et al.  Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. , 2018, Radiology.

[39]  Andrew P. Leynes,et al.  Zero-Echo-Time and Dixon Deep Pseudo-CT (ZeDD CT): Direct Generation of Pseudo-CT Images for Pelvic PET/MRI Attenuation Correction Using Deep Convolutional Neural Networks with Multiparametric MRI , 2017, The Journal of Nuclear Medicine.

[40]  Gaspar Delso,et al.  Repeatability of ZTE Bone Maps of the Head , 2018, IEEE Transactions on Radiation and Plasma Medical Sciences.

[41]  P. Choyke,et al.  Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy , 2018, The Journal of Nuclear Medicine.

[42]  S. Stoeckli,et al.  Maximum Standardized Uptake Value (SUVmax) of Primary Tumor Predicts Occult Neck Metastasis in Oral Cancer , 2018, Scientific Reports.

[43]  A. Alavi,et al.  PET/CT Versus Standard Imaging for Prediction of Survival in Patients with Recurrent Head and Neck Squamous Cell Carcinoma , 2018, The Journal of Nuclear Medicine.

[44]  Richard E. Fan,et al.  Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer. , 2018, Radiology.

[45]  Ciprian Catana,et al.  MR‐assisted PET motion correction in simultaneous PET/MRI studies of dementia subjects , 2018, Journal of Magnetic Resonance Imaging.

[46]  A. Barnes,et al.  Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis , 2018, European heart journal cardiovascular Imaging.

[47]  S. Vasanawala,et al.  18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition , 2018, EJNMMI Research.

[48]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[49]  J. Weinreb,et al.  Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI. , 2017, AJR. American journal of roentgenology.

[50]  M. Schwaiger,et al.  One-Stop-Shop Whole-Body 68Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer , 2018, The Journal of Nuclear Medicine.

[51]  T. Yen,et al.  Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[52]  G. Delso,et al.  Clinical Evaluation of 11C-Met-Avid Pituitary Lesions Using a ZTE-Based AC Method , 2019, IEEE Transactions on Radiation and Plasma Medical Sciences.

[53]  Kathryn J Fowler,et al.  State of the Art PET/MRI: Applications and Limitations - Summary of the First ISMRM/SNMMI Co-Provided Workshop on PET/MRI. , 2019, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  Kathryn J Fowler,et al.  Summary of the First ISMRM–SNMMI Workshop on PET/MRI: Applications and Limitations , 2019, The Journal of Nuclear Medicine.

[55]  Adam E. Hansen,et al.  Clinically Valuable Quality Control for PET/MRI Systems: Consensus Recommendation From the HYBRID Consortium , 2019, Front. Phys..

[56]  John Jones,et al.  A Kalman-Based Approach With EM Optimization for Respiratory Motion Modeling in Medical Imaging , 2019, IEEE Transactions on Radiation and Plasma Medical Sciences.

[57]  I. Burger,et al.  Detection Rate and Localization of Prostate Cancer Recurrence Using 68Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL , 2019, The Journal of Nuclear Medicine.

[58]  Florian Wiesinger,et al.  Attenuation correction using 3D deep convolutional neural network for brain 18F-FDG PET/MR: Comparison with Atlas, ZTE and CT based attenuation correction , 2019, PloS one.

[59]  Reproducibility and Repeatability of Assessment of Myocardial Light Chain Amyloidosis Burden Using 18F-Florbetapir PET/CT. , 2019 .

[60]  Johan Nuyts,et al.  A Quantitative Evaluation of Joint Activity and Attenuation Reconstruction in TOF PET/MR Brain Imaging , 2019, The Journal of Nuclear Medicine.

[61]  P. Høilund-Carlsen,et al.  Hybrid PET/MRI in major cancers: a scoping review , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[62]  M. Tosetti,et al.  An Aristotelian View on MR-Based Attenuation Correction (ARISTOMRAC): Combining the Four Elements , 2019, IEEE Transactions on Radiation and Plasma Medical Sciences.

[63]  F. Prato,et al.  Same day comparison of PET/CT and PET/MR in patients with cardiac sarcoidosis , 2019, Journal of Nuclear Cardiology.

[64]  Murat Aksoy,et al.  Rigid Motion Correction for Brain PET/MR Imaging Using Optical Tracking , 2019, IEEE Transactions on Radiation and Plasma Medical Sciences.

[65]  R. Falk,et al.  Reproducibility and Repeatability of Assessment of Myocardial Light Chain Amyloidosis Burden Using 18F-Florbetapir PET/CT , 2019, Journal of Nuclear Cardiology.

[66]  M. Dweck,et al.  Aortic valve stenosis—multimodality assessment with PET/CT and PET/MRI , 2019, The British journal of radiology.

[67]  Daniela A. Ferraro,et al.  68Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU , 2019, The Journal of Nuclear Medicine.

[68]  Konstantin Nikolaou,et al.  Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation , 2019, Nuklearmedizin.

[69]  M. Rodriguez-Porcel,et al.  Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: The effect of a structured patient preparation protocol , 2019, Journal of Nuclear Cardiology.

[70]  P. Stolzmann,et al.  Use of MRI and FDG‐PET/CT to predict fixation of advanced hypopharyngeal squamous cell carcinoma to prevertebral space , 2019, Head & neck.